These data indicated that CIR potentiated the tumor immune microenvironment by inducing CD8+ TILs to be reprogrammed into more functionally competent cells, which was responsible for better tumor control in prostate cancer‐bearing mice treated by CIR. Here, CD8A is linked to Familial prostate cancer.